Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/31/2025

Finerenone (Kerendia) – Evidence‑Based Cardiorenal Therapy for Adults with Type 2 Diabetes and Chronic Kidney Disease

Cardiorenal Efficacy

  • Finerenone provides dual cardiorenal protection, lowering the risk of kidney disease progression by 23 % and major cardiovascular events by 14 % in patients with type 2 diabetes and CKD who have persistent albuminuria despite maximally tolerated RAS‑inhibitor therapy【1】【2】.
  • In the FIDELIO‑DKD trial, finerenone reduced the composite kidney outcome (kidney failure, sustained ≥40 % eGFR decline, or renal death) by 18 % (HR 0.82, 95 % CI 0.73–0.93)【1】【3】.
  • A pooled analysis of the FIDELITY program ( > 13 000 patients) showed a 23 % relative risk reduction in the composite kidney outcome (kidney failure, sustained ≥57 % eGFR decrease, or renal death) (HR 0.77, 95 % CI 0.67–0.88)【1】【2】.
  • The same pooled FIDELITY data demonstrated a 14 % reduction in the composite cardiovascular endpoint (cardiovascular death, non‑fatal MI, non‑fatal stroke, or heart‑failure hospitalization) (HR 0.86, 95 % CI 0.78–0.95)【1】【2】.
  • In the FIGARO‑DKD trial, finerenone lowered cardiovascular events by 13 % (HR 0.87, 95 % CI 0.76–0.98) among patients with less‑advanced CKD【4】【1】.
  • Finerenone reduced the incidence of new‑onset (symptomatic) heart failure in patients without baseline HFrEF by ≈ 25 % (HR 0.75, 95 % CI 0.57–0.996)【4】.

Evidence level: Phase 3, double‑blind, randomized controlled trials (FIDELIO‑DKD, FIGARO‑DKD) and pooled post‑hoc analysis (FIDELITY) – high‑quality evidence (Class I, Level A).

Patient Selection

  • Indicated for adults with type 2 diabetes, CKD stages 2–4 (eGFR 25–90 mL/min/1.73 m²), and persistent albuminuria (UACR ≥ 30 mg/g) despite maximally tolerated ACE‑inhibitor or ARB therapy【5】【2】.
  • Recommended as an add‑on risk‑based therapy after RAS inhibition and, when tolerated, SGLT2‑inhibitor therapy; can be used as an alternative when SGLT2 inhibitors are contraindicated or not tolerated【5】【2】.

Safety Profile

  • Hyperkalaemia occurs more often with finerenone (14 % vs 6.9 % with placebo), yet permanent discontinuation is low (1.7 % vs 0.6 %) over a median 3‑year follow‑up【1】【2】.
  • No deaths attributable to hyperkalaemia were reported in the pivotal trials【1】【2】.

Evidence level: Safety data derived from the same Phase 3 RCTs and pooled analyses (Class I, Level A).

Dosing and Implementation

  • Initial dose: 10 mg once daily if eGFR 25–60 mL/min/1.73 m²; 20 mg once daily if eGFR > 60 mL/min/1.73 m²【3】.
  • Uptitration: After 1 month, increase from 10 mg to 20 mg when serum potassium ≤ 4.8 mmol/L and eGFR is stable【3】.

Clinical Pitfalls (Avoidable Errors)

  • Do not start finerenone before optimizing RAS‑inhibitor therapy; patients must be on the maximum tolerated dose of an ACE inhibitor or ARB first【5】.
  • Do not overlook the cardiovascular benefits; finerenone reduces major cardiovascular events, heart‑failure hospitalization, and sudden cardiac death, beyond its antiproteinuric effect【4】.
  • Do not consider SGLT2 inhibitors and finerenone interchangeable; they have complementary mechanisms and can be combined for additive cardiorenal protection【5】.

Finerenone in Chronic Kidney Disease: Evidence from Major Trials

Key Clinical Trial Evidence

  • Finerenone significantly reduces both kidney disease progression and cardiovascular events in patients with type 2 diabetes and CKD, supported by Grade A evidence from the FIDELIO-DKD and FIGARO-DKD trials 6, 7
  • The FIDELIO-DKD trial demonstrated an 18% relative risk reduction in composite kidney outcome (kidney failure, sustained ≥40% eGFR decline, or renal death) in patients with type 2 diabetes and more advanced kidney disease 7
  • The FIDELIO-DKD trial also showed a 20% reduction in kidney failure requiring dialysis or transplantation in patients with type 2 diabetes and more advanced kidney disease 6
  • The FIGARO-DKD trial demonstrated a 13% reduction in cardiovascular composite (CV death, MI, stroke, heart failure hospitalization) in patients with type 2 diabetes and less advanced kidney disease 8, 9
  • The FIGARO-DKD trial also showed a 29% reduction in heart failure hospitalizations in patients with type 2 diabetes and less advanced kidney disease 10

Guideline-Based Recommendations

  • The KDIGO Work Group recommends finerenone (Grade 2A) for patients with type 2 diabetes, eGFR >25 mL/min/1.73 m², albuminuria (UACR >30 mg/g), normal serum potassium, and already on maximum tolerated RAS inhibitor dose 6, 11
  • The American Diabetes Association recommends finerenone for patients with type 2 diabetes and CKD, eGFR ≥20 mL/min/1.73 m², UACR ≥30 mg/g despite standard therapy 9, 12
  • The KDOQI Work Group prioritizes SGLT2 inhibitors over finerenone as the next step after RAS inhibitor therapy, but recommends considering finerenone if the patient does not tolerate SGLT2 inhibitor or remains with albuminuria despite SGLT2 inhibitor therapy 11

Safety Profile and Hyperkalemia Management

  • Hyperkalemia occurred more frequently with finerenone, but discontinuation rates remained low, with a permanent discontinuation due to hyperkalemia of only 1.7% vs 0.6% over 3 years 6
  • No deaths were attributed to hyperkalemia in either the FIDELIO-DKD or FIGARO-DKD trials 6, 8

Clinical Implementation Considerations

  • Finerenone is most appropriate for patients at high risk of CKD progression and cardiovascular events, demonstrated by persistent albuminuria despite RAS inhibitor therapy, type 2 diabetes with stage 2-4 CKD, and normal baseline potassium levels 6, 10
  • Finerenone can be safely added to SGLT2 inhibitors for complementary cardiorenal protection, though definitive data on combined benefits remain limited 6, 11

REFERENCES

10

Role of Finerenone in Heart Failure and CKD [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025